Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025 21:04 ET | Source: InnoCare Pharma BEIJING, Dec. 08,…
ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Acronis Partners with Synology to Deliver Three-Year Acronis True Image Essentials with BeeDrive and BeeStation
SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data…
AI UltraProd Announces U.S. Market Entry with Strategic Focus on High-Growth ADU Sector
SecureTech Backing Enables AI UltraProd’s U.S. Accessory Dwelling Unit Beachhead; 2026 Rollout…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9…
EpiEndo Pharmaceutical’s ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in…
Epson creates 150 new jobs in Latvia with the opening of its new European Business Services centre
RIGA, Latvia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Global technology innovator, Epson,…
NOTICE TO DISREGARD — ICARO Media Group
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- We are advised by…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…